CONTEXT AND CAVEATSPrior knowledgeThe National Lung Screening Trial (NLST) is comparing lung cancer mortality among persons who were randomly assigned to screening with reduced dose helical computerized tomography or with chest x-ray.Study designBaseline demographic characteristics of individuals from the NLST were compared with those from the general population who met NLST age and smoking history inclusion criteria who were selected from the Tobacco Use Supplement of the US Census Bureau Current Population Surveys. Eligible participants were aged 55--74 years and were current or former smokers with a cigarette smoking history of at least 30 pack-years.ContributionCharacteristics of the NLST participants were compared with those of a group representing the general population. In both populations, 59% were men. NLST participants were younger than those from the general population, fewer were current smokers, and more than twice as many had a college degree or higher.ImplicationsThe proportion of men and pack-year history were similar between NLST participants and the groups from the general US population that met the major NLST eligibility criteria. There were differences between the two groups on age, education, and smoking status.LimitationsData on personal, family, and occupational history were self-reported and collected with a self-administered questionnaire.From the Editors

Lung cancer remains the leading cause of cancer-related death in both men and women in the United States ([@bib1]). Because prognosis is related to stage, there has been long-standing interest in detecting lung cancer while the disease is still asymptomatic, in the hope that it will be more responsive to treatment. Several observational studies have shown that screening by reduced dose helical computed tomography can detect smaller sized and earlier stage lung cancers than can be detected by symptoms or by screening chest radiographs ([@bib2]--[@bib9]). However, it is not known whether the increased detection of apparently early-stage lung cancers by computerized tomography screening ultimately results in decreased lung cancer--specific mortality. To answer this critical question, the National Lung Screening Trial (NLST) was launched on September 18, 2002. The NLST, a randomized controlled trial designed to determine whether screening with computerized tomography could reduce lung cancer mortality relative to single-view chest radiograph screening, is a multi-institutional trial funded by the US National Cancer Institute (NCI). It is conducted through a collaboration of the NCI Division of Cancer Prevention, which administers the component of NLST known as the Lung Screening Study through a contract mechanism, and the NCI Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, which funds the component administered by the American College of Radiology Imaging Network (ACRIN) through a grant mechanism.

The NLST used a 1:1 ratio to randomly assign individuals to receive either three annual computerized tomography or three annual chest radiograph screens, with follow-up for outcomes for at least 5 years after randomization. Entry criteria, as described previously in detail ([@bib10]), required subjects to be aged between 55 and 74 years and to have a minimum of 30 pack-years of cigarette smoking history at the time of random assignment. Former smokers were required to have quit within 15 years of random assignment. Current smokers were defined as those who still smoked cigarettes regularly. Recruitment was conducted by 33 medical institutions across the United States, with the goal of enrolling a sample representative of the US population at high risk of lung cancer death. Accrual was completed in April 2004, and participants currently are being followed to evaluate clinical outcomes, including vital status and cause of death. The primary endpoint of the NLST is lung cancer--specific mortality, and the trial has 90% power to detect a 20% mortality reduction in the computerized tomography arm relative to the chest radiograph arm. Conclusive results for the primary endpoint are expected by mid-2011. The purpose of this article was to provide a detailed description of demographic, medical, and other characteristics of the NLST study population at the time of randomization.

Participants and Methods
========================

The study was performed after approval by an institutional review board at each institution. Written informed consent was obtained from each subject.

Recruitment Strategies
----------------------

Thirty-three medical institutions participated in the NLST (Clinicaltrials.gov, NCT 00047385) and were widely dispersed throughout the United States ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Participants were recruited by use of techniques that included targeted mailings, local radio and newspaper advertisements, outreach including health fairs and presentations to unions and community groups, NCI and institutional Web sites, Internet-based advertising that listed toll-free numbers for the NCI's Cancer Information Service, and public service television and radio announcements. Local chapters of the American Cancer Society provided recruitment support to many sites.

###### 

National Lung Screening Trial accrual data by study group and screening center[\*](#tblfn1){ref-type="table-fn"}

  Study group                                            Screening center                                                                      Location             Accrual, No. of participants
  ------------------------------------------------------ ------------------------------------------------------------------------------------- -------------------- ------------------------------
  ACRIN                                                  1\. Beth Israel Deaconess Medical Center                                              Boston, MA           629
  2\. Brigham and Women's Hospital                       Boston, MA                                                                            540                  
  3\. Brown University, Rhode Island Hospital            Providence, RI                                                                        827                  
  4\. The Cancer Institute of New Jersey                 New Brunswick, NJ                                                                     88                   
  5\. Dartmouth-Hitchcock Medical Center                 Lebanon, NH                                                                           575                  
  6\. Emory University                                   Atlanta, GA                                                                           1231                 
  7\. Jewish Hospital Rudd Heart and Lung Center         Louisville, KY                                                                        1971                 
  8\. Johns Hopkins University                           Baltimore, MD                                                                         1670                 
  9\. Mayo Clinic, Jacksonville                          Jacksonville, FL                                                                      288                  
  10\. Mayo Clinic, Rochester                            Rochester, MN                                                                         1183                 
  11\. Medical University of South Carolina              Charlestown, SC                                                                       578                  
  12\. Moffitt Cancer Center                             Tampa, FL                                                                             787                  
  13\. Northwestern University                           Chicago, IL                                                                           426                  
  14\. Ochsner Medical Center                            New Orleans, LA                                                                       504                  
  15\. St. Elizabeth Health Center                       Youngstown, OH                                                                        1046                 
  16\. University of California, Los Angeles             Los Angeles, CA                                                                       1587                 
  17\. University of California, San Diego               San Diego, CA                                                                         155                  
  18\. University of Iowa                                Iowa City, IA                                                                         1154                 
  19\. University of Michigan Medical Center             Ann Arbor, MI                                                                         857                  
  20\. University of Pennsylvania                        Philadelphia, PA                                                                      386                  
  21\. University of Texas M.D. Anderson Cancer Center   Houston, TX                                                                           782                  
  22\. Vanderbilt University                             Nashville, TN                                                                         465                  
  23\. Wake Forest University                            Winston-Salem, NC                                                                     1113                 
  Total                                                                                                                                        18 842               
  LSS                                                    24\. Georgetown University Medical Center                                             Washington, DC       1827
                                                         25\. Henry Ford Health System                                                         Detroit, MI          3395
                                                         26\. Marshfield Clinic Research Foundation                                            Marshfield, WI       2520
                                                         27\. Pacific Health Research & Education Institute[†](#tblfn2){ref-type="table-fn"}   Honolulu, HI         2359
                                                         28\. University of Alabama at Birmingham                                              Birmingham, AL       5052
                                                         29\. University of Colorado Denver                                                    Aurora, CO           3743
                                                         30\. University of Minnesota School of Public Health                                  Minneapolis, MN      6618
                                                         31\. University of Pittsburgh Medical Center                                          Pittsburgh, PA       2177
                                                         32\. University of Utah Health Sciences Center                                        Salt Lake City, UT   3159
                                                         33\. Washington University School of Medicine                                         St Louis, MO         3764
                                                         Total                                                                                                      34 614
  Total                                                                                                                                                             53 456

ACRIN = American College of Radiology Imaging Network; LSS = Lung Screening Study.

Formerly known as Pacific Health Research Institute.

![Map of the United States showing National Lung Screening Trial screening centers. The size of the bubble surrounding each site indicates the relative number of participants enrolled at the site. The number adjacent to each site corresponds to the number assigned to the site in [Table 1](#tbl1){ref-type="table"}.](jncidjq434f01_lw){#fig1}

Minority Recruitment Strategies
-------------------------------

Targeted minority recruitment plans were implemented at specific sites on the basis of regional demographic data and site-specific strategies and included advertising at minority-focused conferences and events; direct mailings to minority communities; advertisements in local minority newspapers and on radio stations; use of minority "ambassadors" in community settings; dissemination of information on NLST by minority health-care providers; translation of trial-related materials into Spanish, Chinese dialects, and Farsi; and provision of minority press kits to more than 70 media outlets. These efforts were assisted through collaboration with the NCI Cancer Information Service Partnership Program, the American Public Health Association's Black Caucus of Health Workers, the NCI Spirit of Eagles Program, and the American Cancer Society.

Enrollment and Randomization of Participants
--------------------------------------------

Study eligibility, including smoking history, was assessed through use of an eligibility screener, which was administered by telephone or in-person by trained interviewers. The eligibility screener was designed to allow for the computation of number of pack-years of cigarettes smoked and determination of whether subjects smoked within the past 15 years. Randomization occurred after data coordinating centers confirmed that eligibility criteria had been met for a given individual; participants were then assigned to either the computerized tomography arm or chest radiograph arm in a 1:1 ratio, stratifying by site, sex, and 5-year age group. Stratified randomization was accomplished by use of a block size of six or eight, with block size chosen at random. At the time of the enrollment, participants filled out a questionnaire that contained questions on personal history of selected diseases, including respiratory diseases, cardiovascular diseases, stroke, and diabetes; family history of lung cancer; occupational history (jobs and industries either previously demonstrated or thought to be associated with increased risk of lung disease or lung cancer); weight and height; and demographic factors such as education and marital status. Compliance with questionnaire completion was 99.6% (53 267 of the 53 456 participants) and was similar in both study arms.

Comparison Between the NLST Population and the General Population at Risk for Lung Cancer
-----------------------------------------------------------------------------------------

To assess whether the NLST population was representative of the overall US population that was likely to be eligible for the trial, we used the Census Department's Tobacco Use Supplement of the Continuing Population Survey for 2002--2004, the years corresponding to the period of NLST enrollment ([@bib11]). The Tobacco Use Supplement contains questions about respondents' past and present cigarette smoking, captures demographic information and other behavioral data, and contains information on a scientifically selected, nationally representative sample of approximately 240 000 individuals. Using the responses to Tobacco Use Supplement questions, we identified the subset of respondents who were aged 55--74 years, had smoking history of at least 30 pack-years, and were either current smokers or former smokers who had quit within the past 15 years. For this subset of 9090 individuals, we evaluated the distribution of age, sex, race, Hispanic ethnicity, marital status, and education, as well as smoking status (current vs former) and pack-years of cigarettes smoked. We compared distributions of participants identified through the Tobacco Use Supplement with those of NLST participants.

Results
=======

Study Accrual
-------------

NLST enrollment began on September 18, 2002 and was completed on April 26, 2004, 4 months before the targeted completion date. The study enrolled 53 456 individuals, with 9016 subjects being enrolled in 2002, 38 584 in 2003, and 5856 in 2004. Of the 53 456 participants, 34 614 (65%) were accrued from Lung Screening Study sites and 18 842 (35%) from ACRIN sites ([Table 1](#tbl1){ref-type="table"}). As of November 30, 2009, 192 enrolled persons who were thought to be eligible at the time of randomization were determined to be ineligible. Common reasons for ineligibility included computerized tomography within 18 months before enrollment (n = 68), nonsmoker or quit more than 15 years before randomization (n = 23), participation in another cancer screening trial (n = 28), recent antibiotic use (n = 17), insufficient pack-years (n = 12), diagnosis of cancer in the 5 years before randomization (n = 14), and age older or younger than the required range (n = 12). These randomized but ineligible subjects are included in the study and in the current analysis.

Comparison of the Lung Screening Study and ACRIN study populations showed that the two groups were quite similar with respect to demographics: 13 630 (72%) of 18 842 ACRIN and 25 604 (74%) of 34 614 Lung Screening Study subjects were younger than 65 years and 8440 (45%) of ACRIN and 13 483 (39%) of Lung Screening Study subjects were women. A total of 9514 (50%) of ACRIN and 16 265 (47%) of Lung Screening Study subjects were current smokers.

Demographic Characteristics
---------------------------

Of the total of 53 456 participants, 26 733 were randomly assigned to chest radiograph screening and 26 723 were randomly assigned to computerized tomography. The distribution of sex and age by study arm is shown in [Table 2](#tbl2){ref-type="table"}. A total of 31 533 (59%) of participants were men and 39 234 (73%) were younger than 65 years. Mean age of the entire cohort was 61.4 years (standard deviation = 5.0 years). Median age was 60 years (interquartile range = 57--65 years). Because randomization was stratified by sex and 5-year age group, the participant numbers are virtually identical within these categories across study arms.

###### 

Demographic factors and baseline smoking status of participants in the National Lung Screening Trial by screening arm[\*](#tblfn3){ref-type="table-fn"}

  Characteristic                                      Spiral CT, No. (%)   X-ray, No. (%)   Total, No. (%)
  --------------------------------------------------- -------------------- ---------------- ----------------
  Total                                               26 723 (100.0)       26 733 (100.0)   53 456 (100.0)
  Age at randomization                                                                      
      \<55,[†](#tblfn4){ref-type="table-fn"} y        2 (0.0)              3 (0.0)          5 (0.0)
      55--59 y                                        11 440 (42.8)        11 421 (42.7)    22 861 (42.8)
      60--64 y                                        8170 (30.6)          8198 (30.7)      16 368 (30.6)
      65--69 y                                        4756 (17.8)          4762 (17.8)      9518 (17.8)
      70--74 y                                        2352 (8.8)           2345 (8.8)       4697 (8.8)
      \>74,[†](#tblfn4){ref-type="table-fn"} y        1 (0.0)              3 (0.0)          4 (0.0)
      Missing                                         2 (0.0)              1 (0.0)          3 (0.0)
  Sex                                                                                       
      Male                                            15 770 (59.0)        15 763 (59.0)    31 533 (59.0)
      Female                                          10 953 (41.0)        10 970 (41.0)    21 923 (41.0)
  Race                                                                                      
      White                                           24 289 (90.9)        24 260 (90.7)    48 549 (90.8)
      Black or African American                       1196 (4.5)           1182 (4.4)       2378 (4.4)
      Asian                                           559 (2.1)            536 (2.0)        1095 (2.0)
      American Indian or Alaskan Native               92 (0.3)             98 (0.4)         190 (0.4)
      Native Hawaiian or other Pacific Islander       91 (0.3)             102 (0.4)        193 (0.4)
      More than one race                              333 (1.2)            346 (1.3)        679 (1.3)
      Missing                                         163 (0.6)            209 (0.8)        372 (0.7)
  Hispanic ethnicity                                                                        
      Hispanic or Latino                              479 (1.8)            456 (1.7)        935 (1.7)
      Neither Hispanic nor Latino                     26 080 (97.6)        26 040 (97.4)    52 120 (97.5)
      Missing                                         164 (0.6)            237 (0.9)        401 (0.8)
  Marital status                                                                            
      Never married                                   1255 (4.7)           1203 (4.5)       2458 (4.6)
      Married or living as married                    17 815 (66.7)        17 775 (66.5)    35 590 (66.6)
      Widowed                                         1985 (7.4)           1982 (7.4)       3967 (7.4)
      Separated                                       338 (1.3)            330 (1.2)        668 (1.2)
      Divorced                                        5194 (19.4)          5238 (19.6)      10 432 (19.5)
      Missing                                         136 (0.5)            205 (0.8)        341 (0.6)
  Educational status                                                                        
      ≤8th grade                                      363 (1.4)            392 (1.5)        755 (1.4)
      9th--11th grade                                 1279 (4.8)           1218 (4.6)       2497 (4.7)
      High school graduate or GED                     6274 (23.5)          6437 (24.1)      12 711 (23.8)
      Post--high school training, excluding college   3768 (14.1)          3726 (13.9)      7494 (14.0)
      Associate's degree or some college              6262 (23.4)          6152 (23.0)      12 414 (23.2)
      Bachelor's degree                               4506 (16.9)          4442 (16.6)      8948 (16.7)
      Graduate school                                 3927 (14.7)          3964 (14.8)      7891 (14.8)
      Other                                           227 (0.8)            241 (0.9)        468 (0.9)
      Missing                                         117 (0.4)            161 (0.6)        278 (0.5)
  CDC categories                                                                            
      Underweight (\<18.5 kg/m^2^)                    245 (0.9)            252 (0.9)        497 (0.9)
      Normal (18.5--24.9 kg/m^2^)                     7517 (28.1)          7331 (27.4)      14 848 (27.8)
      Overweight (25--29.9 kg/m^2^)                   11 265 (42.2)        11 491 (43.0)    22 756 (42.6)
      Obese (≥30 kg/m^2^)                             7555 (28.3)          7462 (27.9)      15 017 (28.1)
      Missing                                         141 (0.5)            197 (0.7)        338 (0.6)
  Smoking status                                                                            
      Current smokers                                 12 869 (48.2)        12 910 (48.3)    25 779 (48.2)
      Former smokers                                  13 854 (51.8)        13 823 (51.7)    27 677 (51.8)
       Quit within 4 y of study entry                 3944 (14.8)          3947 (14.8)      7891 (14.8)
       Quit 4--9.9 y before study entry               4598 (17.2)          4645 (17.4)      9243 (17.3)
       Quit 10--15 y before study entry               5257 (19.7)          5165 (19.3)      10 422 (19.5)
       Missing                                        55 (0.2)             66 (0.2)         121 (0.2)

CDC = Center for Disease Control; CT = computerized tomography; GED = General Equivalency Diploma.

Participants in the age groups of younger than 55 years and older than 74 years were ineligible.

The distribution of race, Hispanic or Latino ethnicity, marital status, educational status, and body mass index by study arm is shown in [Table 2](#tbl2){ref-type="table"}. The distribution of these characteristics was similar across study arms. Most individuals (48 549 or 91%) in the cohort were white, 2378 (4.4%) were black, and 935 (1.7%) were of Hispanic or Latino ethnicity. Only 3252 (6%) did not have a high school degree, and 16 839 (approximately 32%) had at least a college degree. A total of 15 017 (28%) of the NLST subjects were obese by Center for Disease Control criteria (ie, body mass index ≥ 30 kg/m^2^).

Smoking History
---------------

Details of smoking history in these subjects are presented in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}. Smoking patterns were similar across study arms. A total of 27 677 (52%) of the cohort of 53 456 participants were former smokers and 25 779 (48%) were current smokers. Among the 27 677 former smokers, 7891 (29%) reported quitting within 4 years of study entry. Smoking status showed a strong age trend, with the percentage of current smokers decreasing from 54% among those aged 55--59 years to 47% among those aged 60--64 years, 41% among those aged 65--69 years, and 38% among those aged 70--74 years. Median pack-year history of smoking was similar for current smokers (48 pack-years) and former smokers (50 pack-years). Duration of smoking was similar for current smokers and for former smokers, with a median of 43 years for both arms.

###### 

Baseline smoking frequency per pack-year history of participants in the National Lung Screening Trial by study arm[\*](#tblfn5){ref-type="table-fn"}

  Screening group and characteristic   No. of pack-years smoked   No. of cigarettes smoked per day   No. of years of smoking                                                
  ------------------------------------ -------------------------- ---------------------------------- ------------------------- -------- -------- -------- -------- -------- --------
  Spiral CT                                                                                                                                                                 
      No.                              12 869                     13 854                             26 723                    12 869   13 854   26 723   12 868   13 853   26 721
      Mean                             55.52                      56.52                              56.04                     25.98    30.77    28.47    43.44    42.74    43.08
      Minimum                          18                         21                                 18                        10       10       10       13       12       12
      First quartile                   40.0                       38.8                               39.0                      20.0     20.0     20.0     40.0     38.0     39.0
      Median                           48.0                       49.0                               48.0                      20.0     30.0     25.0     43.0     43.0     43.0
      Third quartile                   66.0                       67.5                               66.0                      30.0     40.0     35.0     47.0     48.0     47.0
      Maximum                          235                        295                                295                       100      140      140      67       69       69
  X-ray                                                                                                                                                                     
      No.                              12 910                     13 823                             26 733                    12 910   13 823   26 733   12 910   13 823   26 733
      Mean                             55.30                      56.51                              55.93                     25.90    30.76    28.41    43.41    42.77    43.08
      Minimum                          25                         15                                 15                        10       10       10       16       10       10
      First quartile                   40.0                       38.0                               39.0                      20.0     20.0     20.0     40.0     38.0     39.0
      Median                           48.0                       49.5                               48.0                      20.0     30.0     25.0     43.0     43.0     43.0
      Third quartile                   64.5                       68.0                               66.3                      30.0     40.0     35.0     47.0     48.0     47.0
      Maximum                          412                        568                                568                       201      258      258      70       69       70
  Total                                                                                                                                                                     
      No.                              25 779                     27 677                             53 456                    25 779   27 677   53 456   25 778   27 676   53 454
      Mean                             55.41                      56.52                              55.98                     25.94    30.77    28.44    43.43    42.75    43.08
      Minimum                          18                         15                                 15                        10       10       10       13       10       10
      First quartile                   40.0                       38.3                               39.0                      20.0     20.0     20.0     40.0     38.0     39.0
      Median                           48.0                       49.5                               48.0                      20.0     30.0     25.0     43.0     43.0     43.0
      Third quartile                   65.0                       68.0                               66.0                      30.0     40.0     35.0     47.0     48.0     47.0
      Maximum                          412                        568                                568                       201      258      258      70       69       70

CT = computerized tomography.

Occupational Exposure and Medical History
-----------------------------------------

Information concerning work experience in occupations and industries thought to increase risk of lung disease or lung cancer is shown in [Table 4](#tbl4){ref-type="table"}. Approximately 28% of participants in each arm reported working in at least one of the listed industries and/or occupations that have been associated with increased risk of lung disease or cancer. The most common of these industries and occupations were farming (10.7% or 5699 participants), chemicals or plastics manufacturing (6.2% or 3317 participants), welding (5.6% or 2975 participants), and painting (5.3% or 2813 participants). Approximately 5% of participants had worked with asbestos. The median duration of employment was 10 years or less for each industry and occupation, except for firefighting (which was 12 years in computerized tomography arm and 11 years in chest radiograph arm). Work history differed by sex, with 11 957 (38%) of the 31 533 men vs 3048 (14%) of the 21 923 women reporting a work history in any of the listed occupations.

###### 

Work experience of participants in the National Lung Screening Trial by screening arm[\*](#tblfn6){ref-type="table-fn"}

  Type of work                          Spiral CT     X-ray   Total                                
  ------------------------------------- ------------- ------- ------------- ------ --------------- ------
  Asbestos work                         1238 (4.6)    8.0     1288 (4.8)    10.0   2526 (4.7)      9.0
  Baking                                603 (2.3)     3.0     551 (2.1)     3.0    1154 (2.2)      3.0
  Butchering/meat packing               572 (2.1)     3.0     593 (2.2)     4.0    1165 (2.2)      3.0
  Chemicals or plastics manufacturing   1642 (6.1)    8.0     1675 (6.3)    7.0    3317 (6.2)      8.0
  Coal mining                           169 (0.6)     8.0     162 (0.6)     9.0    331 (0.6)       8.0
  Cotton or jute processing             194 (0.7)     4.0     201 (0.8)     4.0    395 (0.7)       4.0
  Farming                               2837 (10.6)   10.0    2862 (10.7)   10.0   5699 (10.7)     10.0
  Firefighting                          477 (1.8)     12.0    513 (1.9)     11.0   990 (1.9)       12.0
  Flour, feed, or grain milling         290 (1.1)     4.0     297 (1.1)     4.0    587 (1.1)       4.0
  Foundry or steel milling              1159 (4.3)    6.0     1089 (4.1)    5.0    2248 (4.2)      5.0
  Hard rock mining                      205 (0.8)     5.0     213 (0.8)     5.0    418 (0.8)       5.0
  Painting                              1382 (5.2)    5.0     1431 (5.4)    5.0    2813 (5.3)      5.0
  Sandblasting                          456 (1.7)     4.0     457 (1.7)     4.0    913 (1.7)       4.0
  Welding                               1505 (5.6)    10.0    1470 (5.5)    10.0   2975 (5.6)      10.0
  Any of the above occupations          7448 (27.9)           7557 (28.3)          15 005 (28.1)   

CT = computerized tomography; ME = median exposure.

The history of selected diseases, including respiratory, cardiovascular and malignant diseases, as well as family history of cancer, is presented in [Table 5](#tbl5){ref-type="table"}. Results were similar across arms. With respect to respiratory diseases, 9326 (17%) of the 53 456 subjects reported a history of chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema and approximately 22% in each arm reported a history of pneumonia. A history of cardiovascular disease was quite common, with 18 930 (35%) reporting a history of hypertension and 6797 (13%) reporting a history of heart disease or heart attack; in addition, 5174 (10%) reported a history of diabetes.

###### 

History of selected respiratory and cardiovascular diseases, selected malignancies, and family history of lung cancer, among participants in the National Lung Screening Trial by screening arm[\*](#tblfn7){ref-type="table-fn"}

  Disease                                                          Spiral CT, No. (%)   X-ray, No. (%)   Total, No. (%)
  ---------------------------------------------------------------- -------------------- ---------------- ----------------
  Respiratory and cardiovascular disease                                                                 
      Asbestosis                                                   276 (1.0)            257 (1.0)        533 (1.0)
      Asthma first diagnosed as an adult                           1666 (6.2)           1653 (6.2)       3319 (6.2)
      Asthma first diagnosed as a child                            935 (3.5)            974 (3.6)        1909 (3.6)
      Bronchiectasis                                               854 (3.2)            901 (3.4)        1755 (3.3)
      Chronic bronchitis                                           2592 (9.7)           2545 (9.5)       5137 (9.6)
      COPD                                                         1347 (5.0)           1343 (5.0)       2690 (5.0)
      Emphysema                                                    2056 (7.7)           2037 (7.6)       4093 (7.7)
      Chronic bronchitis, emphysema, or COPD                       4674 (17.5)          4652 (17.4)      9326 (17.4)
      Diabetes                                                     2594 (9.7)           2580 (9.7)       5174 (9.7)
      Fibrosis of the lung                                         70 (0.3)             58 (0.2)         128 (0.2)
      Heart disease or heart attack                                3445 (12.9)          3352 (12.5)      6797 (12.7)
      Pneumonia                                                    5930 (22.2)          5879 (22.0)      11 809 (22.1)
      Sarcoidosis                                                  48 (0.2)             49 (0.2)         97 (0.2)
      Silicosis                                                    30 (0.1)             27 (0.1)         57 (0.1)
      Tuberculosis                                                 281 (1.1)            296 (1.1)        577 (1.1)
      Hypertension                                                 9378 (35.1)          9552 (35.7)      18 930 (35.4)
      Stroke                                                       753 (2.8)            759 (2.8)        1512 (2.8)
      Any of the above diseases                                    17 567 (65.7)        17 552 (65.7)    35 119 (65.7)
  Malignancies                                                                                           
      Bladder cancer                                               112 (0.4)            128 (0.5)        240 (0.4)
      Breast cancer[†](#tblfn8){ref-type="table-fn"}               352 (3.2)            396 (3.6)        748 (3.4)
      Cervical cancer[†](#tblfn8){ref-type="table-fn"}             364 (3.3)            404 (3.7)        768 (3.5)
      Breast or cervical cancer[†](#tblfn8){ref-type="table-fn"}   703 (6.4)            783 (7.1)        1486 (6.8)
      Colorectal cancer                                            111 (0.4)            119 (0.4)        230 (0.4)
      Esophageal cancer                                            12 (0.0)             8 (0.0)          20 (0.0)
      Kidney cancer                                                37 (0.1)             31 (0.1)         68 (0.1)
      Cancer of the larynx                                         20 (0.1)             26 (0.1)         46 (0.1)
      Nasal cancer                                                 11 (0.0)             10 (0.0)         21 (0.0)
      Oral cancer                                                  51 (0.2)             52 (0.2)         103 (0.2)
      Cancer of the pharynx                                        3 (0.0)              5 (0.0)          8 (0.0)
      Any head and neck cancer                                     82 (0.3)             89 (0.3)         171 (0.3)
      Pancreatic cancer                                            4 (0.0)              3 (0.0)          7 (0.0)
      Stomach cancer                                               12 (0.0)             15 (0.1)         27 (0.1)
      Thyroid cancer                                               36 (0.1)             47 (0.2)         83 (0.2)
      Any of the above cancers                                     1073 (4.0)           1194 (4.5)       2267 (4.2)
  Family history of lung cancer                                                                          
      Any first-degree relative[‡](#tblfn9){ref-type="table-fn"}   5815 (21.8)          5806 (21.7)      11 621 (21.7)
      Two or more first-degree relatives                           885 (3.3)            863 (3.2)        1748 (3.3)

COPD = chronic obstructive pulmonary disease; CT = computerized tomography.

Female participants only.

A first-degree relative was defined as a parent, brother, sister, or children of an individual (National Cancer Institute---<http://www.cancer.gov/dictionary/>).

Data on family history of lung cancer were reported by each participant ([Table 5](#tbl5){ref-type="table"}). A family history of lung cancer (in a parent, sibling, or child) was reported by 11 621 (22%) of the 53 546 subjects, with 1748 (3%) reporting two or more relatives with a lung cancer history. This prevalence was similar in the two study arms.

Characteristics of the NLST population as compared with those of the overall NLST-eligible US population as measured with the Tobacco Use Supplement are shown in [Table 6](#tbl6){ref-type="table"}. The NLST population was younger than the US eligible population (73% were younger than 65 years vs 65%, respectively), but the populations were similar in terms of sex (59% of both populations were men). The proportions of blacks and Hispanics were roughly similar in the two populations. NLST subjects were substantially more educated, with the percentage having less than a high school education being 6% in the NLST cohort and 21% in the Tobacco Use Supplement cohort and the percentage with at least a college degree being 32% in the NLST cohort and 14% in the Tobacco Use Supplement cohort. NLST subjects were also slightly more likely to be married (67% vs 60%, respectively). Geographically, the NLST cohort, compared with the Tobacco Use Supplement cohort, had a greater proportion of Midwesterners (39% vs 29%, respectively) and smaller percentages of Southerners (24% vs 33%, respectively) and Northeasterners (16% vs 21%, respectively). With respect to smoking history, subjects in the NLST cohort were less likely to be current smokers than those in the Tobacco Use Supplement cohort (48% vs 57%, respectively), but both cohorts had similar median pack-years of cigarette smoking (48 pack-years vs 47 pack-years, respectively).

###### 

Comparison of the National Lung Screening Trial (NLST) cohort with the NLST-eligible US population from the Tobacco Use Supplement (TUS) of the US Census Bureau Current Population Surveys[\*](#tblfn10){ref-type="table-fn"}

  Characteristic                           NLST   TUS
  ---------------------------------------- ------ ------
  Male, %                                  59.0   58.5
  Age group, %                                    
      55--59 y                             42.8   35.2
      60--64 y                             30.6   29.3
      65--69 y                             17.8   20.8
      70--74 y                             8.8    14.7
  Race/ethnicity, %                               
      Black                                4.4    5.5
      Hispanic or Latino, %                1.7    2.4
  Education, %                                    
      Less than high school                6.1    21.3
      College degree or higher             31.5   14.4
  Married, %                               66.6   60.0
  Current smoker, %                        48.2   57.1
  Median pack-years of cigarette smoking   48.0   47.0
  US region, %                                    
   Northeast                               16.3   21.1
   Midwest                                 39.2   28.8
   South                                   23.9   33.0
   West                                    20.6   17.2

Estimates were derived from the TUS of the US Bureau Current Population Survey for the years of NLST enrollment and were calculated by restricting the survey population to those respondents who met the NLST age and smoking eligibility criteria.

Discussion
==========

The validity of a randomized controlled trial rests on the ability of the randomization process to produce study arms that are similar with regard to characteristics that are or could be related to the outcome of interest. Our analysis of the baseline characteristics of the NLST population has demonstrated that the randomization process in NLST produced two very similar groups of participants ([Tables 2](#tbl2){ref-type="table"}--[5](#tbl5){ref-type="table"}). For example, the distributions of smoking characteristics, past occupational exposure, disease history, and family history of lung cancer were essentially indistinguishable between the two study arms. Demographically, the baseline age and sex distributions in the two arms were virtually identical because of stratified randomization on these factors. In addition, the race, ethnicity, education, and marital status profiles were similar in the two arms.

It is useful to evaluate whether the results of a randomized controlled trial are generalizable to the population from which the study participants were drawn, also known as the "base population." Generalizability can be assessed in part by examining whether certain characteristics of the study sample are distributed similarly to those in the base population. To assess generalizability, we compared distributions of characteristics that are known or suspected to affect risk of lung cancer--specific death among NLST participants with those from respondents to the Tobacco Use Supplement of the Current Population Survey from the Census Department who met the NLST age and smoking eligibility criteria ([@bib11]). For several key factors, including sex, race, ethnicity, and pack-years of smoking, the NLST and Tobacco Use Supplement populations were quite similar. The similarity of the percentages of black and Hispanic subjects indicated that targeted minority recruitment efforts were quite successful. Although there was no specific criterion in NLST to ensure that screening centers were selected to ensure geographic representativeness, the distribution of NLST subjects across the four regions of the country was generally reflective of the eligible population, with a modest overweighting of the Midwest and slight underweighting of the other regions. There is no reason to believe, however, that these minor geographic differences will affect findings in such a manner that results are not able to be generalized.

Research participants are often healthier than those to whom study results are to be generalized. Such a phenomenon can bias study outcomes if the fact that study participants are healthier results in a different outcome than would have been observed if the health of participants was similar to that of the base population. Distribution of certain characteristics did suggest that the NLST population might be healthier than the base population. For example, NLST subjects were somewhat younger (73% were younger than age 65 years vs 65% in the base population), were less likely to be current smokers (48% vs 57%, respectively), and were better educated (6% with less than a high school education vs 21%, respectively). Whether these differences will affect the generalizability of study findings is unknown, but it seems unlikely that these relatively minor differences will result in a meaningful bias. Adjustments for such differences can be made through statistical modeling. Other randomized prevention or screening trials, such as the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, have shown similar effects ([@bib12]) ([@bib13]). For example, in the PLCO Trial, the participants were better educated than the overall eligible population ([@bib12]).

NLST data collected on smoking, family history of lung cancer, occupation and/or industry experience, and specific previous diseases will be used for epidemiological analyses of lung cancer incidence and mortality. The relationship of smoking, the strongest risk factor, to lung cancer will be explored in great detail. Numerous inhalational exposures, either known or suspected to be associated with lung cancer ([@bib14]), will also be investigated. However, details of inhalational exposure were not recorded. More than 2500 of the NLST participants reported work-related exposure (median duration = 9 years) to asbestos, the environmental inhalational exposure most definitively and strongly associated with lung cancer ([@bib15]). This cohort is one of the largest groups of asbestos-exposed subjects being actively followed for lung cancer ([@bib16],[@bib17]) and will permit further evaluation of the well-known relationships among asbestos exposure, cigarette smoking, and lung cancer.

A family history of lung cancer is also associated with an increased risk of lung cancer. A systematic review of case--control and cohort studies ([@bib18]) indicated that the presence of a relative with lung cancer is associated with a statistically significantly increased risk of lung cancer. Risk appears to be greatest in relatives of persons diagnosed at a young age and in those with multiple affected family members. However, it remains unclear how much of this increased risk can be attributed to genetics and how much to the fact that relatives of smokers are more likely to be cigarette smokers or exposed to second-hand smoke. Twenty-two percent of NLST participants had a family history of lung cancer, and 3% had two or more first-degree relatives with lung cancer. This large cohort may permit further evaluation of the role of family history in the etiology of lung cancer. The NLST also will generate data to evaluate several medical conditions known to be associated with lung cancer. Among these conditions, the most salient is COPD ([@bib15]), present by self-report (including reports of chronic bronchitis and emphysema) in more than 9300 NLST participants. The presence of emphysema (self-reported in almost 4100 NLST participants) appears to be a greater risk factor for lung cancer than chronic airway obstruction ([@bib19],[@bib20]). NLST ancillary studies should assist in confirming the extent of increased risk that is associated with the diagnosis of COPD and with computerized tomography--determined emphysema. Other risk factors for lung cancer present in the NLST cohort include asbestosis (reported by 533 participants), lung fibrosis (128 participants), silicosis (57 participants), and history of head and neck cancer (171 participants).

Limitations of the NLST as an epidemiological cohort include the fact that data on personal, family, and occupational history are self-reported and collected by use of a self-administered questionnaire. However, these limitations are common to most large studies of this type, and there was excellent participant compliance (99.6%) with completion of questionnaires.

We conclude that the NLST cohort is at high risk of lung cancer and is broadly reflective of the general US smoking population. The randomization process in the NLST resulted in study arms that have similar distributions of many known and suspected risk factors for lung cancer. In addition to evaluating the relative impact of chest radiographic and chest computerized tomography screening on lung cancer--specific mortality, the NLST cohort can also be used to clarify other important questions regarding lung cancer epidemiology.
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